AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2059974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrices containing 1,500 ppm F as sodium monofluorophosphate (SMFP)
Number of subjects: 0
Study 2059974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrices containing 2,500 ppm F as sodium monofluorophosphate (SMFP)
Number of subjects: 0
Study 2059974 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ enamel insert model
Number of subjects: 0
Study 2059974 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluoride pharmacokinetics
Number of subjects: 0
Study 2059974 — intervention group
Group type: EXPERIMENTAL
Intervention: F uptake to demineralised enamel
Number of subjects: 0
Study 6131254 — intervention group
Group type: EXPERIMENTAL
Intervention: Solarium exposure (suntan treatment)
Number of subjects: 0
Study 6131254 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched concurrent controls)
Number of subjects: 0
Study 31865625 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of visual and auditory stimuli
Number of subjects: 56
Study 31865625 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 31495232 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Shift (NS)
Number of subjects: 22
Study 31495232 — intervention group
Group type: COMPARATOR
Intervention: Day Shift/Days Off (DSDO)
Number of subjects: 22
Study 29388414 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervicoscopy (group A)
Number of subjects: 170
Study 29388414 — intervention group
Group type: COMPARATOR
Intervention: No additional examination (group B)
Number of subjects: 170
Study 26316575 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 179
Study 25186131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible incobotulinumtoxinA (Xeomin®) injections at intervals of 6-20 weeks, with doses of ≤ 50 U/eye for blepharospasm and 120 U or 240 U for CD.
Number of subjects: 1282
Study 25186131 — intervention group
Group type: COMPARATOR
Intervention: IncobotulinumtoxinA 120 U or 240 U for cervical dystonia.
Number of subjects: 1282
Study 25186131 — intervention group
Group type: COMPARATOR
Intervention: Placebo for cervical dystonia.
Number of subjects: 1282
Study 21472883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 60
Study 21472883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham laser)
Number of subjects: 60
Study 19195793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response in schizophrenia patients
Number of subjects: 60
Study 19195793 — intervention group
Group type: COMPARATOR
Intervention: Cortisol response in matched controls
Number of subjects: 60
Study 19195793 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate and mean arterial pressure response
Number of subjects: 60
Study 17518213 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsyllabic method (self-paced version)
Number of subjects: 63
Study 17518213 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsyllabic method (automatic syllable identification version)
Number of subjects: 63
Study 17518213 — intervention group
Group type: COMPARATOR
Intervention: Control method (based on phonemic awareness, assisted reading, and other psycholinguistic exercises)
Number of subjects: 63
Study 15370635 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-side plaque test (Dentocult SM)
Number of subjects: 65
Study 15370635 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-side saliva test
Number of subjects: 65
Study 15370635 — intervention group
Group type: COMPARATOR
Intervention: Laboratory method
Number of subjects: 65
Study 11250995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide treatment (5-year duration)
Number of subjects: 2867
Study 11250995 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2867
Study 9648698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP) 200 microg four times daily for 6 days
Number of subjects: 199
Study 9648698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 9648698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP)
Number of subjects: 199
Study 9648698 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with positive cultures for S. pneumoniae, H. influenzae, or M. catarrhalis
Number of subjects: 199
Study 7978538 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta‐adrenergic agonists
Number of subjects: 0
Study 7978538 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 7978538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 0
Study 7978538 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroChambers and InspirEase kits
Number of subjects: 0
Study 7978538 — intervention group
Group type: COMPARATOR
Intervention: Asthma mortality rates
Number of subjects: 0
Study 2537582 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day for 4 weeks)
Number of subjects: 9
Study 2537582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31264940 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive-behavioral therapy (CBT) for anxiety
Number of subjects: 35
Study 31045449 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic diet recommended
Number of subjects: 20
Study 31045449 — intervention group
Group type: COMPARATOR
Intervention: Neutropenic diet not recommended
Number of subjects: 20
Study 31045449 — intervention group
Group type: COMPARATOR
Intervention: Neutropenic diet not addressed
Number of subjects: 20
Study 31045449 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence backing recommendations
Number of subjects: 20
Study 28235970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure Self-Directed (PSD) intervention
Number of subjects: 200
Study 28235970 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Directed (GSD) intervention
Number of subjects: 200
Study 25668777 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of cycling training (n=10)
Number of subjects: 20
Study 25668777 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 15‐minute cycling session
Number of subjects: 20
Study 25668777 — intervention group
Group type: COMPARATOR
Intervention: No training (control group, n=10)
Number of subjects: 20
Study 23054601 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of hand weight during reaching tasks
Number of subjects: 0
Study 23054601 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to the same perturbation
Number of subjects: 0
Study 21205247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator at 0.9 mg/kg
Number of subjects: 0
Study 21205247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) 100 ml
Number of subjects: 0
Study 18285727 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV pp65 antigen
Number of subjects: 67
Study 18285727 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV IgM antibody
Number of subjects: 67
Study 17121345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training
Number of subjects: 41
Study 17121345 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic endurance training
Number of subjects: 41
Study 15228257 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ-AS (Chloroquine combined with Artesunate)
Number of subjects: 300
Study 15228257 — intervention group
Group type: COMPARATOR
Intervention: CQ (Chloroquine alone)
Number of subjects: 300
Study 10859547 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conditions
Number of subjects: 34
Study 10859547 — intervention group
Group type: COMPARATOR
Intervention: 2D conditions
Number of subjects: 34
Study 8686975 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg every 12 hours
Number of subjects: 111
Study 8686975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg every 12 hours
Number of subjects: 111
Study 8686975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg, plus rifampin, 300 mg every 12 hours
Number of subjects: 111
Study 8686975 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 111
Study 8686975 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 111
Study 8686975 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin plus rifampin
Number of subjects: 111
Study 2051576 — intervention group
Group type: EXPERIMENTAL
Intervention: M1-blocker; pirenzepine
Number of subjects: 30
Study 2051576 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-blocker; ranitidine
Number of subjects: 30
Study 2051576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 6341272 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention programme
Number of subjects: 6000
Study 6341272 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger cohort
Number of subjects: 6000
Study 6341272 — intervention group
Group type: EXPERIMENTAL
Intervention: Older cohort
Number of subjects: 6000
Study 30394006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) supplementation (2 × 500 mg/d)
Number of subjects: 31
Study 30394006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29994792 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression gloves
Number of subjects: 32
Study 29994792 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control)
Number of subjects: 32
Study 28376754 — intervention group
Group type: EXPERIMENTAL
Intervention: TDR surgery
Number of subjects: 144
Study 28376754 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation
Number of subjects: 144
Study 26684653 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 portions FV/day for 16-weeks
Number of subjects: 83
Study 26684653 — intervention group
Group type: COMPARATOR
Intervention: 2 portions FV/day
Number of subjects: 83
Study 26684653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (5 portions/day and 2 portions/day)
Number of subjects: 83
Study 23228626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization (STB) exercises for 6 weeks
Number of subjects: 25
Study 21247971 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise at 45% peak power, n=20
Number of subjects: 61
Study 21247971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (30 sec on, 30 sec off at 90% peak power), n=21
Number of subjects: 61
Study 21247971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (10 min intermittent at 90% peak power then 10 min continuous at 45% peak power), n=20
Number of subjects: 61
Study 18715391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 8100 automated blood pressure machine
Number of subjects: 0
Study 18715391 — intervention group
Group type: COMPARATOR
Intervention: Manual sphygmomanometer
Number of subjects: 0
Study 16542056 — intervention group
Group type: COMPARATOR
Intervention: MK‐0767 (1-80 mg single doses)
Number of subjects: 8
Study 16542056 — intervention group
Group type: COMPARATOR
Intervention: MK‐0767 (0.3-25 mg multiple doses once daily for 14 days)
Number of subjects: 8
Study 16542056 — intervention group
Group type: COMPARATOR
Intervention: MK‐0767 (25 mg multiple doses once daily for 14 days)
Number of subjects: 8
Study 12850240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users
Number of subjects: 30
Study 12850240 — intervention group
Group type: COMPARATOR
Intervention: Non-users (Control)
Number of subjects: 30
Study 10940094 — intervention group
Group type: EXPERIMENTAL
Intervention: Solubilized ibuprofen, 400 mg
Number of subjects: 154
Study 10940094 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen, 1000 mg
Number of subjects: 154
Study 10940094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 9512820 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 9512820 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12
Study 9512820 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 12
Study 8374092 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 59
Study 8374092 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 3484773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil, 1,000 mg single‐dose
Number of subjects: 5
Study 3484773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil, 500 mg twice a day for three days
Number of subjects: 5
Study 3484773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil, 500 mg twice a day for seven days
Number of subjects: 5
Study 3484773 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMZ), 320‐1,600 mg single‐dose
Number of subjects: 5
Study 3484773 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMZ), 160‐800 mg twice a day for three days
Number of subjects: 5
Study 29618116 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the rVLPFC
Number of subjects: 44
Study 29618116 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study 29618116 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the rVLPFC
Number of subjects: 44
Study 26508702 — intervention group
Group type: EXPERIMENTAL
Intervention: 15LEU (70/15/180/30 g protein-leucine-carbohydrate-fat)
Number of subjects: 12
Study 26508702 — intervention group
Group type: EXPERIMENTAL
Intervention: 5LEU (23/5/180/30 g protein-leucine-carbohydrate-fat)
Number of subjects: 12
Study 26508702 — intervention group
Group type: COMPARATOR
Intervention: 15LEU and 5LEU
Number of subjects: 12
Study 26508702 — intervention group
Group type: COMPARATOR
Intervention: Protein-leucine ingestion
Number of subjects: 12
Study 25239122 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone nutrition support (ATNS) counseling
Number of subjects: 75
Study 25239122 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving ATNS phone calls 14 weeks after enrollment
Number of subjects: 75
Study 23650508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude de-acclimatization syndrome evaluation on the 3rd, 50th, and 100th days after return to low altitude.
Number of subjects: 137
Study 23650508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects returning to Kunming
Number of subjects: 137
Study 23650508 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine blood and blood gas tests, myocardial zymograms assay
Number of subjects: 137
Study 23650508 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude de-acclimatization syndrome
Number of subjects: 137
Study 21092098 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathways (CP) as complex intervention including formative evaluation, evidence-based key interventions, and support for CP implementation
Number of subjects: 398
Study 21092098 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 398
Study 19035086 — intervention group
Group type: EXPERIMENTAL
Intervention: PHS group
Number of subjects: 80
Study 19035086 — intervention group
Group type: COMPARATOR
Intervention: Mesh-plug group
Number of subjects: 80
Study 16697496 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid enriched parenteral nutrition
Number of subjects: 24
Study 16697496 — intervention group
Group type: COMPARATOR
Intervention: soy bean lipid emulsion
Number of subjects: 24
Study 14607440 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise stress test the day after coronary stenting
Number of subjects: 1000
Study 14607440 — intervention group
Group type: COMPARATOR
Intervention: No stress test
Number of subjects: 1000
Study 11012479 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, Tetracycline, Bismuth, and Clarithromycin (OTBC)
Number of subjects: 31
Study 11012479 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin, Omeprazole, Tetracycline, and Bismuth (OTBA)
Number of subjects: 31
Study 8746285 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/day) for 28 days
Number of subjects: 101
Study 8746285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 1402620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 25 mg orally, three times daily for 8 days
Number of subjects: 30
Study 1402620 — intervention group
Group type: COMPARATOR
Intervention: Control group (furosemide and rehydration alone)
Number of subjects: 30
Study 3768084 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (Salbutax)
Number of subjects: 12
Study 3768084 — intervention group
Group type: COMPARATOR
Intervention: Preparation B (commercially available formulation)
Number of subjects: 12
Study 31642985 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related behavioral activation therapy (F-BA) for 12 months
Number of subjects: 744
Study 31642985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 744
Study 31642985 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related behavioral activation therapy (F-BA)
Number of subjects: 744
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtuse angled earlobes
Number of subjects: 1000
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute angled earlobes
Number of subjects: 1000
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Right angled earlobes
Number of subjects: 1000
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute angled earlobes in males
Number of subjects: 1000
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtuse angled earlobes in females
Number of subjects: 1000
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Attached type earlobes
Number of subjects: 1000
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Attached type earlobes in males
Number of subjects: 1000
Study 30392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Attached type earlobes in females
Number of subjects: 1000
Study 30392739 — intervention group
Group type: COMPARATOR
Intervention: Comparison of attached vs free type earlobes
Number of subjects: 1000
Study 30392739 — intervention group
Group type: COMPARATOR
Intervention: Comparison of earlobe types between sexes
Number of subjects: 1000
Study 25684312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME)
Number of subjects: 53
Study 25684312 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 53
Study 25118092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 9
Study 25118092 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 9
Study 21297126 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiation therapy (RT) with gefitinib and tipifarnib
Number of subjects: 0
Study 27945892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing Mycobacterium w, administered 0.1 ml intradermally on a weekly basis for 6 to 10 weeks.
Number of subjects: 91
Study 27945892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing Mycobacterium w
Number of subjects: 91
Study 27945892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 91
Study 12017405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER (two 500-mg tablets once daily for 7 days)
Number of subjects: 176
Study 12017405 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg once daily for 7 days)
Number of subjects: 176
Study 12017405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER
Number of subjects: 176
Study 12017405 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 176
Study 12017405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER and Trovafloxacin
Number of subjects: 176
Study 9720828 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive companion during labour for 1 hour
Number of subjects: 16
Study 9720828 — intervention group
Group type: COMPARATOR
Intervention: No supportive companion during labour for 1 hour (control)
Number of subjects: 16
Study 8018004 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of heparin nomogram
Number of subjects: 0
Study 8018004 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy with nomogram
Number of subjects: 0
Study 8018004 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy (rtPA, APSAC) with heparin
Number of subjects: 0
Study 2596812 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 320
Number of subjects: 39
Study 2596812 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate 320 mgI/ml
Number of subjects: 39
Study 824553 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic exercise therapy with bencyclane (treatment group, n = 45)
Number of subjects: 91
Study 824553 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n = 46)
Number of subjects: 91
Study 12094921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 5mg kg(‐1)
Number of subjects: 100
Study 12094921 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (Control Group)
Number of subjects: 100
Study 29789415 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tubes
Number of subjects: 34
Study 29789415 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bands
Number of subjects: 34
Study 29789415 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bodybuilding
Number of subjects: 34
Study 26963737 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+NFT
Number of subjects: 92
Study 26963737 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 92
Study 26963737 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study 25006684 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 60
Study 25006684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22611116 — intervention group
Group type: EXPERIMENTAL
Intervention: M1: Taken 'OFF' CPAP with the view to stay 'OFF'
Number of subjects: 177